NCT01458119View on ClinicalTrials.gov

Open-Label Phase 3 Long-Term Safety Study of Migalastat

PHASE3TerminatedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

October 14, 2011

Primary Completion Date

February 17, 2016

Study Completion Date

February 17, 2016

Conditions
Fabry Disease
Interventions
DRUG

migalastat hydrochloride

Oral capsule QOD

Trial Locations (25)

2100

Copenhagen

2650

Edegem

3050

Parkville

5000

Adelaide

10016

New York

11451

Cairo

15213

Pittsburgh

22030

Fairfax

30322

Atlanta

49525

Grand Rapids

60611

Chicago

66160

Kansas City

75246

Dallas

92380

Garches

97239

Portland

98195

Seattle

02114

Boston

B1629ODT

Pilar

90035-903

Porto Alegre

H4J 1C5

Montreal

00168

Roma

08025

Barcelona

06500

Ankara

NW3 2QG

London

M6 8HD

Salford

Sponsors
All Listed Sponsors
lead

Amicus Therapeutics

INDUSTRY